Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer

Schütz F, Fasching P, Welslau M, Hartkopf AD, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Kolberg HC, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Müller V (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Geburtshilfe und Frauenheilkunde Georg Thieme Verlag

Book Volume: 79

Pages Range: 1079-1089

Journal Issue: 10

DOI: 10.1055/a-1001-9925

Abstract

The further development of therapies for women with early breast cancer is progressing far more slowly than in the case of patients with advanced breast cancer and is additionally delayed compared to developments in metastatic breast cancer. Nonetheless, significant advancements have been able to be recorded recently. This review summarises the latest developments in view of the most recent publications and professional conferences. For hormone-receptor-positive patients, new aspects for the duration of antihormone therapy and with regard to the benefits of multigene tests have been published. In the case of HER2-positive patients, the value of post-neoadjuvant therapy and de-escalation of the therapy is discussed. In patients with triple-negative breast cancer, there is a question of whether the knowledge of the biological background of a homologous recombination deficiency (HRD) helps develop new therapies for this subtype. In particular the use of a BRCA1/2 mutation or the biological characteristic HRD as a potential motive for therapy plays a role here in specifying the significance of platinum therapy and therapy with PARP inhibitors.

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Ruprecht-Karls-Universität Heidelberg DE Germany (DE) Universitätsklinikum Ulm DE Germany (DE) Klinikum rechts der Isar DE Germany (DE) Universitätsklinikum Würzburg DE Germany (DE) Agaplesion Markus Krankenhaus DE Germany (DE) Universitätsklinikum Düsseldorf DE Germany (DE) Eberhard Karls Universität Tübingen DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Marienhospital Bottrop DE Germany (DE) OncoConsult DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) Kooperatives Brustzentrum Paderborn DE Germany (DE) Klinikum Aschaffenburg DE Germany (DE) ClinSol GmbH & Co.KG DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE)

How to cite

APA:

Schütz, F., Fasching, P., Welslau, M., Hartkopf, A.D., Wöckel, A., Lux, M.P.,... Müller, V. (2019). Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtshilfe und Frauenheilkunde, 79(10), 1079-1089. https://doi.org/10.1055/a-1001-9925

MLA:

Schütz, Florian, et al. "Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer." Geburtshilfe und Frauenheilkunde 79.10 (2019): 1079-1089.

BibTeX: Download